Written by Jane Aubrey
The FDA’s accelerated approval of Bristol Myers Squibb’s Zenbexus gives multiple-myeloma treatment a new class of medicine and creates an important test for whether deep molecular responses can translate into lasting clinical benefit. The drug, iberdomide, is the first approved cereblon-modulating protein degrader, or CELMoD, and it enters a treatment setting where patients frequently need effective options after a first relapse.
Bristol Myers Squibb announced the approval on August 13. Zenbexus is authorized in combination with daratumumab and hyaluronidase-fihj plus dexamethasone for adults with multiple myeloma who have received at least one prior therapy, including a proteasome inhibitor and an immunomodulatory agent. The indication is not a full approval: it is an accelerated approval contingent on confirmation of clinical benefit in future evidence.
The supporting result is notable. In the Phase 3 EXCALIBER-RRMM study, the Zenbexus combination produced minimal-residual-disease-negative complete responses in 41% of patients, compared with 21% for the comparator regimen of daratumumab, bortezomib and dexamethasone. That comparison involved 207 patients in the Zenbexus group and 213 in the comparator group, with a median follow-up of 16 months.
Minimal residual disease, or MRD, refers to cancer cells that remain after treatment but are below the detection threshold of conventional tests. In multiple myeloma, MRD-negative complete response is a particularly deep response measure. It is clinically meaningful because fewer detectable malignant cells may correlate with longer disease control. But it is not the same as proof that patients live longer or remain progression-free for a longer period. That is why progression-free survival remains a co-primary endpoint in EXCALIBER-RRMM and why the confirmatory evidence is central to the approval’s ultimate value.
The scientific significance lies in the CELMoD mechanism. These drugs modulate cereblon, a component of the cell’s protein-degradation machinery, in an effort to alter disease-relevant protein pathways and enhance immune activity. Bristol Myers Squibb has long experience in myeloma immunomodulatory drugs; Zenbexus represents an attempt to extend that foundation with a more targeted protein-degradation platform. If the class can deliver stronger efficacy while remaining manageable in routine practice, it could reshape treatment sequencing after relapse.
The safety profile makes the word “manageable” important. The approved combination carries boxed warnings for embryo-fetal toxicity and serious venous and arterial thromboembolism. Zenbexus is distributed through a restricted REMS program. In the pivotal study, neutropenia occurred in 90.2% of treated patients and infections occurred in 78.9%; serious adverse reactions occurred in 58.3% of patients. Pneumonia, neutropenia, febrile neutropenia and sepsis were among the major concerns, while fatal adverse reactions occurred in 4.9% of treated patients.
Those figures do not diminish the importance of the efficacy signal, but they place it in context. Relapsed or refractory myeloma is difficult to treat and patients often arrive with prior treatment exposure, disease-related immune dysfunction and cumulative toxicity. The practical question for clinicians will be whether monitoring, prophylaxis, dose modification and supportive care can preserve the regimen’s benefit outside the carefully managed environment of a clinical trial.
The approval may also affect the broader myeloma pipeline. Bristol Myers Squibb has another investigational CELMoD, mezigdomide, under FDA review in a separate combination, while the EXCALIBER study continues to assess progression-free survival. More options are valuable in a disease where relapse remains expected, but they also make comparative sequencing more complex. Physicians will need clearer evidence on which patients benefit most, how durable MRD-negative responses are and how Zenbexus compares with cellular therapies, bispecific antibodies and established triplets.
Zenbexus is a real advance because it introduces a new therapeutic class with a compelling early efficacy measure. The next phase is more consequential: translating a deep response signal into verified, durable patient benefit while ensuring that the regimen’s safety burden remains acceptable in everyday care.
